Plasma phosphorylated tau — the blood-based biomarker detecting p-tau181, p-tau217, and p-tau231 enabling non-invasive Alzheimer's disease diagnosis, screening, and treatment monitoring with 85-95% concordance to CSF and PET amyloid status representing the fastest-growing biomarker in the global neurological biomarker market — creates the most diagnostically accessible market...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek